TJ: You must be smoking something strong. Do some basic DD and beware of spreading rumors:
As far as I can tell (but do your own DD), ACTC has 500,000,000 common shares authorized with 120,000,000 outstanding, and 50,000,000 preferred shares authorized. Todays's market cap = $10.2M. If only the outstanding shares are considered, then $7/share = $840,000,000. Combine that with assets at best $8-10M, and with annual revenue only about $600k (with salaries of CEO and Chief Scientist about $800K/yr), then does this rumor make any sense/cents???
By the way, GERN has only 89,000,000 outstanding shares, today's market cap = $15M, and $2.8M revenue in 2008.
Again, what makes sense/cents here?
Now compound this with the Fed gobbledegook - Obama's EO basicaly does nothing more that eliminate what restricted Fed funding was avalable via Bush's EO since the 1995 (Clinton) Dickey Amendment prohibits all Fed funding for ESCs. Despite the March 9, 2009 executive order from President Obama, which removed the restriction against federal funding of stem cell research, the Wicker-Dickey Amendment remains an obstacle for federally-funded researchers seeking to create their own stem cell lines. Nothing can happen, even with NIH being responsible for determinig expenditures, until Congress overturns or modifies the Dickey amendment. As it is now, zero Fed funding is available, so nothing major will or can occur until the whole process evolves. UNLESS, with ACTCs proprietary process for ESC's intact and no damage, perhaps private and institutional funding will break loose - once it is well known and proven that the ESCs are not damaged or destroyed. Then the only stickler involves cloning, and what that really means (e.g., cloning a kidney or finger vs a human or animal.
Regardless, do your own DD, and beware of spreading false or misleading info. You'll find that the ACTC iHub Board has some well informed and long term members. All herein is IMHO.
News 
Market Data 
Discover 
